Frost & Sullivan Market Insight: The Biobanking Community to Increasingly Require Innovative Products in Bio-Storage Applications
The global proliferation of disease-based regional and national biobanks for clinical research has triggered a massive interest in long-term sample storage conditions. Simultaneously, it has spawned a requirement for good storage practices and standard operating procedures (SOPs). Biobanks need to carefully evaluate complaint storage, sample shipment and data management procedures during the formulation of a strategic sample management plan. They are acknowledging the need to maintain sample integrity and viability by adopting new storage methodologies and solutions that will guarantee better sample quality to the research community.
Traditional methods of storage include storing samples in laboratory freezers at -20 °C, -80 °C and liquid nitrogen. These processes are being largely automated with the help of radio frequency identification (RFID) and micro electromechanical systems (MEMS) technologies.
In recent times, however, there has been a perceptible shift in preference towards room temperature storage. Vendors such as Biomatrica and IntegenX Inc. are developing reagents to stabilise the DNA and RNA so they last long under ambient temperature. This process effectively eliminates the need for freezer units and extra storage space.
With time, it becomes difficult for biobanks and biorepositories to track and retrieve samples stored at ultra-low temperatures. Traditional methods of storage involve barcoding microplates, wherein the retrieval of a single sample from a microplate would involve thawing the entire plate, which will affect the freeze–thaw cycles of other samples. Under the new system, therefore, sample storage is done in microtubes and individual vials.
Earlier, equipment and robotic arms were designed to handle microplates; now, systems are flexible enough to cherry pick individual microtubes. For instance, TTP LabTech provides high-capacity storage for automated biobanking at -80 °C; this system is capable of selecting a sample within 60 seconds. Other notable mentions are Hamilton Storage, which provides a scalable and flexible third-generation automated system for biobanking; and Matrical Bioscience, which provides automated sample storage management and retrieval systems. Most of the storage systems today offer robotic interfaces inside a chilled atmosphere to prevent the disturbance of unused samples.
“Biobanks’ interest in dry-state storing and eliminating freeze-thaw cycles has led to the introduction of many patented automated biobanking storage platforms for the samples requiring -20 °C and -80 °C. These platforms have the facility to store samples in both microplates and micro-tube format,” noted Frost & Sullivan Healthcare Senior Research Analyst Divyaa Ravishankar. “They ensure the continuous monitoring of samples even during picking.”
Most of the companies involved in long-term sample storage processes have indicated high use of Thermo Fisher Scientific and Micronic B.V’s 2D barcoded tubes. These tubes are permanently laser etched to provide traceability. In certain cases, however, too much of frost can hinder readability. To resolve this challenge, RFID and the MEMS technology have been incorporated to enhance tractability even under frosted conditions. While Sysmex Bioscience employs RFID for its product, Icebreaker cryovial, and Bluechiip Limited uses MEMS technology. These advancements provide real-time alerts and a temperature history of the sample, as it is important that the sample does not undergo wide temperature variations during a given period.
For storage of tissue samples, Provia Laboratories provides innovative human tissue biospecimen storage containers and kit solutions called Proviasette. These have been designed for efficient storage and tracking, thereby increasing the productivity of tissue biobanks.
“However, many challenges still lie ahead for solution vendors. Given that no two biobanks function similarly, it is tough to generalise a technology platform,” said Ravishankar. “A lot of custom work is required to suit the workflow processes of a biobank. At the same time, obtaining funding and ensuring financial maintenance of the biobanking infrastructure will become tougher in the long run.”
Biobanking comes with the inherent challenges of continuous monitoring of clinical samples and associated sample information, which requires a highly integrated set up. In addition, an exponential increase in the volume of samples is leading to issues with storage capacity and duration.
While small quantities of samples could contaminate the researchers handling them, large quantities of samples could task the researcher with maintaining consistency. These challenges are making a strong case for replacing manual protocols with automated ones.
The lack of high-quality and clinically annotated samples highlights the need for standardising sample handling and storage protocols globally. The paucity of standardised quality checking protocols for the pre-analytical phase creates roadblocks when comparing and sharing samples, especially when specimen volumes are likely to be high.
Biobanking also grapples with several ethical issues such as consent, personal integrity, privacy protection, safety of samples and access to data and stored samples. The laws and regulations pertaining to ownership, intellectual property rights and commercialisation discourage the use of resource material. Furthermore, the cross-border shipping of samples requires consent from donors. With the sole aim of safeguarding the donor information, governments in Norway and Sweden allow the analysis of samples but discourage their long-term storage.
All in all, a totally integrated system of hardware, software and consumable tools will be the way to ‘smart biobanking’. With the introduction of many technologies, forward-looking biobanks can retain sample quality/integrity by employing smart and smooth sample handling systems. “The cornerstone of every biorepository lies in the efficiency of its freezer inventory software or the LIMS employed,” observed Ravishankar. “The key objective is to enable researchers to locate and use biospecimens.”
If you are interested in more information on this Market Insight — Biobanking: Challenging Sample Integrity Measures Drive the Uptake of Innovative Products for Bio-Storage Applications, please send an email to Anna Zanchi, Corporate Communications, at [email protected]
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance